Abstract
High-dose pulse chlorambucil was given orally at a dose of 16 mg/m2 daily for 5 consecutive days each month, as reported by Cadman et al. It was used to treat 33 patients with advanced, low-grade, non-Hodgkin's lymphoma. With median follow-up of 4.2+ years, 70% of the patients achieved objective response. Eleven of 24 patients with follicular small cleaved cell lymphoma (FSCL) had pathological complete response; nine of 24 with FSCL and three of seven with small lymphocytic lymphoma had partial response. Median disease-free survival was 28 months. Actuarial survival for all patients was 60% at 5 years from initiation of therapy. Treatment toxicity was minimal. Pulse chlorambucil is an effective and minimally toxic palliative therapy for advanced FSCL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1029-1031 |
| Number of pages | 3 |
| Journal | Cancer treatment reports |
| Volume | 71 |
| Issue number | 11 |
| State | Published - 1987 |
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research